Toremifene – (89778-26-7)

Toremifene is a selective estrogen receptor modulator (SERM) primarily used in the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown-status tumors.

Toremifene is a mixed agonist–antagonist of the estrogen receptor, with estrogenic effects in bone, the liver, and the uterus, and antiestrogenic effects in the breasts. It is a triphenylethylene derivative and is closely related to tamoxifen. Introduced in 1997, it was the first new antiestrogen to be introduced since tamoxifen in 1978.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Toremifene
https://pubchem.ncbi.nlm.nih.gov/compound/3005573
https://www.medchemexpress.com/toremifene.html
https://www.medkoo.com/products/16925
https://www.mayoclinic.org/drugs-supplements/toremifene-oral-route/description/drg-20066456
https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-161